Nicorandil and GI ulceration

Nicorandil (Ikorel), indicated for the prevention and treatment of angina, is associated with a risk of gastrointestinal ulceration, including perianal ulceration, according to a recent safety update from the MHRA.

Mouth ulceration has long been a recognised adverse effect of nicorandil, however healthcare professionals should now consider nicorandil treatment as a possible cause in patients with symptoms of gastrointestinal ulceration.

The ulceration can be severe and, in a few patients, has led to perforation. Ulcers are refractory to treatment and only respond to withdrawal of nicorandil. Withdrawal should take place only under the supervision of a cardiologist.

Further information: MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more